Prev Close | 51.40 |
Open | 51.13 |
Day Low/High | 47.88 / 51.40 |
52 Wk Low/High | 14.01 / 53.70 |
Volume | 1.70M |
Avg Volume | 2.21M |
Prev Close | 51.40 |
Open | 51.13 |
Day Low/High | 47.88 / 51.40 |
52 Wk Low/High | 14.01 / 53.70 |
Volume | 1.70M |
Avg Volume | 2.21M |
Exchange | NASDAQ |
Shares Outstanding | 154.03M |
Market Cap | 7.78B |
EPS | -1.90 |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...
Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.
With the election resolved, biotech could be ripe for consolidation.
I have been warning about weakening breadth and narrow leadership for weeks and months. What have we gotten? Eight straight days (in a row) down for the first time since 2008. But, with stocks suffering from election uncertainties and given the ...
These small-caps are woefully undervalued after getting shellacked in October.
It was good to stand in for Doug Kass today. Lots of lively conversation this Friday (over 200 comments), most of them around the markets as well....:-). The Daily Diary was certainly more interesting than today's market, which ended mixed as it clo...
This sector is one of the few areas of the market where you'll find myriad compelling values.
"You see, in this world there's two kinds of people, my friend: Those with loaded guns and those who dig. You dig." -- Blondie in "The Good, the Bad and the Ugly." I did very little today. Markets were higher from the get-go and seemed "stuck" nea...
It was a nostalgic morning. A 20th anniversary. My first TST column in 1997. There was no rest for the weary as the crude and oil markets turned on a dime after OPEC announced a production cut. I, Jim Cramer and others are skeptical about this - s...
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
These stocks have made U-turns in the past week.
I warned in yesterday's Good, Bad and Ugly against taking shots on speculative stocks like biotech. Well, the biotech space is getting pummeled today. For example, Sage Therapeutics is down 11.8% as I write this, while Acadia Pharmaceuticals is off ...
The sector seems to be rebounding after tumbling by more than 40%.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Buyers live higher, sellers live lower. Markets are still Fed-centric and governed by the last lean by Yellen. Ali Ali Ali! Here's a very good column from El Capitan. Apple (AAPL) is Crapple (Part Deux) Fastenal (FAST) is always a good proxy for...
These mid-caps would do well by themselves, but could tempt bigger companies.
It is hard to see much growth in the market overall, until earnings growth returns.
I started the day with an updated and still ursine market update: "Hey, Let's Be Careful Out There." A new investment short -- England, via iShares MSCI United Kingdom (EWU). EWU as a short went on my Best Ideas List. Jim Chanos and I are thinkin...
These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.
Today and yesterday are good examples of the fondness of crowds, and that buyers live higher and sellers live lower. Stocks closed at the day's highs, despite a reversal in the price of crude oil and some weak domestic data and disappointing retail ...
Another strong market day. The issue of taxes was front and center today. Here are some of my takes: My Take on Corporate Taxes Man Up, Allergan Shareholders Who Loses in Pfizer/Allergan Deal's Demise? I remain manifestly bearish, in the belief ...
I started the day today by dissing the banks. Then, I unfriended Facebook (FB) by making it my Short Trade of the Week. Finally, I offered another critical post about auto stocks. Hey, at least I'm consistent! And at least I like Op...
Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.
They are oversold and lately been on the move.
Take this, bulls! This, too! I ended the day with my highest net short exposure in more than 12 months. Committed in view, or to be committed? You decide. The U.S. dollar declined in value today. This seems to be a key element of the bulls' argume...
U.S. futures are climbing Monday after major indices experienced a dip in trading last week.